The Impact of regulation on the development of new products in the pharmaceutical sector: New products and services. analysis of regulations shaping new markets : first interim report
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Karlsruhe
Fraunhofer ISI, Institute, Systems, and Innovation Research
[2003]
|
| Schlagworte: | |
| Beschreibung: | 103 S. Ill. |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV035788794 | ||
| 003 | DE-604 | ||
| 005 | 20110131 | ||
| 007 | t | ||
| 008 | 091026s2003 a||| |||| 00||| eng d | ||
| 035 | |a (OCoLC)213006810 | ||
| 035 | |a (DE-599)BVBBV035788794 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91S | ||
| 084 | |a WIR 600f |2 stub | ||
| 084 | |a WIR 497f |2 stub | ||
| 245 | 1 | 0 | |a The Impact of regulation on the development of new products in the pharmaceutical sector |b New products and services. analysis of regulations shaping new markets : first interim report |c Bernhard Bührlen, Knut Blind, Klaus Menrad ... |
| 264 | 1 | |a Karlsruhe |b Fraunhofer ISI, Institute, Systems, and Innovation Research |c [2003] | |
| 300 | |a 103 S. |b Ill. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Legislation, Drug / economics / Canada | |
| 650 | 4 | |a Legislation, Drug / economics / Europe | |
| 650 | 4 | |a Legislation, Drug / economics / United States | |
| 650 | 4 | |a Drug Industry / economics / Canada | |
| 650 | 4 | |a Drug Industry / economics / Europe | |
| 650 | 4 | |a Drug Industry / economics / United States | |
| 650 | 4 | |a Drug Industry / legislation & jurisprudence / Canada | |
| 650 | 4 | |a Drug Industry / legislation & jurisprudence / Europe | |
| 650 | 4 | |a Drug Industry / legislation & jurisprudence / United States | |
| 650 | 4 | |a Drug Industry / economics / Canada | |
| 650 | 4 | |a Drug Industry / economics / Europe | |
| 650 | 4 | |a Drug Industry / economics / United States | |
| 650 | 4 | |a Drug Industry / legislation & jurisprudence / Canada | |
| 650 | 4 | |a Drug Industry / legislation & jurisprudence / Europe | |
| 650 | 4 | |a Drug Industry / legislation & jurisprudence / United States | |
| 650 | 4 | |a Drug Industry |x economics |z Canada | |
| 650 | 4 | |a Drug Industry |x economics |z Europe | |
| 650 | 4 | |a Drug Industry |x economics |z United States | |
| 650 | 4 | |a Drug Industry |x legislation & jurisprudence |z Canada | |
| 650 | 4 | |a Drug Industry |x legislation & jurisprudence |z Europe | |
| 650 | 4 | |a Drug Industry |x legislation & jurisprudence |z United States | |
| 650 | 4 | |a Legislation, Drug / economics / Canada | |
| 650 | 4 | |a Legislation, Drug / economics / Europe | |
| 650 | 4 | |a Legislation, Drug / economics / United States | |
| 650 | 4 | |a Legislation, Drug |x economics |z Canada | |
| 650 | 4 | |a Legislation, Drug |x economics |z Europe | |
| 650 | 4 | |a Legislation, Drug |x economics |z United States | |
| 650 | 0 | 7 | |a Forschung und Entwicklung |0 (DE-588)4017897-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Regulierung |0 (DE-588)4201190-5 |2 gnd |9 rswk-swf |
| 651 | 4 | |a Europa | |
| 651 | 4 | |a Kanada | |
| 651 | 4 | |a USA | |
| 689 | 0 | 0 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 0 | 1 | |a Forschung und Entwicklung |0 (DE-588)4017897-3 |D s |
| 689 | 0 | 2 | |a Regulierung |0 (DE-588)4201190-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Bührlen, Bernhard |e Sonstige |0 (DE-588)122398815 |4 oth | |
| 700 | 1 | |a Blind, Knut |d 1965- |e Sonstige |0 (DE-588)123118905 |4 oth | |
| 700 | 1 | |a Menrad, Klaus |e Sonstige |4 oth | |
| 710 | 2 | |a Fraunhofer-Institut für Systemtechnik und Innovationsforschung |e Sonstige |0 (DE-588)2071565-1 |4 oth | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-018648171 | ||
Datensatz im Suchindex
| _version_ | 1804140728315543552 |
|---|---|
| any_adam_object | |
| author_GND | (DE-588)122398815 (DE-588)123118905 |
| building | Verbundindex |
| bvnumber | BV035788794 |
| classification_tum | WIR 600f WIR 497f |
| ctrlnum | (OCoLC)213006810 (DE-599)BVBBV035788794 |
| discipline | Wirtschaftswissenschaften |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03296nam a2200745 c 4500</leader><controlfield tag="001">BV035788794</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20110131 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">091026s2003 a||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)213006810</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035788794</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91S</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WIR 600f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WIR 497f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The Impact of regulation on the development of new products in the pharmaceutical sector</subfield><subfield code="b">New products and services. analysis of regulations shaping new markets : first interim report</subfield><subfield code="c">Bernhard Bührlen, Knut Blind, Klaus Menrad ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Karlsruhe</subfield><subfield code="b">Fraunhofer ISI, Institute, Systems, and Innovation Research</subfield><subfield code="c">[2003]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">103 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug / economics / Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug / economics / Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug / economics / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics / Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics / Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / legislation & jurisprudence / Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / legislation & jurisprudence / Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / legislation & jurisprudence / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics / Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics / Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / economics / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / legislation & jurisprudence / Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / legislation & jurisprudence / Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / legislation & jurisprudence / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">economics</subfield><subfield code="z">Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">economics</subfield><subfield code="z">Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">economics</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">legislation & jurisprudence</subfield><subfield code="z">Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">legislation & jurisprudence</subfield><subfield code="z">Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">legislation & jurisprudence</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug / economics / Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug / economics / Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug / economics / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug</subfield><subfield code="x">economics</subfield><subfield code="z">Canada</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug</subfield><subfield code="x">economics</subfield><subfield code="z">Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug</subfield><subfield code="x">economics</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Forschung und Entwicklung</subfield><subfield code="0">(DE-588)4017897-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Regulierung</subfield><subfield code="0">(DE-588)4201190-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">Europa</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">Kanada</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Forschung und Entwicklung</subfield><subfield code="0">(DE-588)4017897-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Regulierung</subfield><subfield code="0">(DE-588)4201190-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bührlen, Bernhard</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)122398815</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blind, Knut</subfield><subfield code="d">1965-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)123118905</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Menrad, Klaus</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Fraunhofer-Institut für Systemtechnik und Innovationsforschung</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)2071565-1</subfield><subfield code="4">oth</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-018648171</subfield></datafield></record></collection> |
| geographic | Europa Kanada USA |
| geographic_facet | Europa Kanada USA |
| id | DE-604.BV035788794 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T22:04:35Z |
| institution | BVB |
| institution_GND | (DE-588)2071565-1 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-018648171 |
| oclc_num | 213006810 |
| open_access_boolean | |
| owner | DE-91S DE-BY-TUM |
| owner_facet | DE-91S DE-BY-TUM |
| physical | 103 S. Ill. |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | Fraunhofer ISI, Institute, Systems, and Innovation Research |
| record_format | marc |
| spelling | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report Bernhard Bührlen, Knut Blind, Klaus Menrad ... Karlsruhe Fraunhofer ISI, Institute, Systems, and Innovation Research [2003] 103 S. Ill. txt rdacontent n rdamedia nc rdacarrier Legislation, Drug / economics / Canada Legislation, Drug / economics / Europe Legislation, Drug / economics / United States Drug Industry / economics / Canada Drug Industry / economics / Europe Drug Industry / economics / United States Drug Industry / legislation & jurisprudence / Canada Drug Industry / legislation & jurisprudence / Europe Drug Industry / legislation & jurisprudence / United States Drug Industry economics Canada Drug Industry economics Europe Drug Industry economics United States Drug Industry legislation & jurisprudence Canada Drug Industry legislation & jurisprudence Europe Drug Industry legislation & jurisprudence United States Legislation, Drug economics Canada Legislation, Drug economics Europe Legislation, Drug economics United States Forschung und Entwicklung (DE-588)4017897-3 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Regulierung (DE-588)4201190-5 gnd rswk-swf Europa Kanada USA Pharmazeutische Industrie (DE-588)4045696-1 s Forschung und Entwicklung (DE-588)4017897-3 s Regulierung (DE-588)4201190-5 s DE-604 Bührlen, Bernhard Sonstige (DE-588)122398815 oth Blind, Knut 1965- Sonstige (DE-588)123118905 oth Menrad, Klaus Sonstige oth Fraunhofer-Institut für Systemtechnik und Innovationsforschung Sonstige (DE-588)2071565-1 oth |
| spellingShingle | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report Legislation, Drug / economics / Canada Legislation, Drug / economics / Europe Legislation, Drug / economics / United States Drug Industry / economics / Canada Drug Industry / economics / Europe Drug Industry / economics / United States Drug Industry / legislation & jurisprudence / Canada Drug Industry / legislation & jurisprudence / Europe Drug Industry / legislation & jurisprudence / United States Drug Industry economics Canada Drug Industry economics Europe Drug Industry economics United States Drug Industry legislation & jurisprudence Canada Drug Industry legislation & jurisprudence Europe Drug Industry legislation & jurisprudence United States Legislation, Drug economics Canada Legislation, Drug economics Europe Legislation, Drug economics United States Forschung und Entwicklung (DE-588)4017897-3 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Regulierung (DE-588)4201190-5 gnd |
| subject_GND | (DE-588)4017897-3 (DE-588)4045696-1 (DE-588)4201190-5 |
| title | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report |
| title_auth | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report |
| title_exact_search | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report |
| title_full | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report Bernhard Bührlen, Knut Blind, Klaus Menrad ... |
| title_fullStr | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report Bernhard Bührlen, Knut Blind, Klaus Menrad ... |
| title_full_unstemmed | The Impact of regulation on the development of new products in the pharmaceutical sector New products and services. analysis of regulations shaping new markets : first interim report Bernhard Bührlen, Knut Blind, Klaus Menrad ... |
| title_short | The Impact of regulation on the development of new products in the pharmaceutical sector |
| title_sort | the impact of regulation on the development of new products in the pharmaceutical sector new products and services analysis of regulations shaping new markets first interim report |
| title_sub | New products and services. analysis of regulations shaping new markets : first interim report |
| topic | Legislation, Drug / economics / Canada Legislation, Drug / economics / Europe Legislation, Drug / economics / United States Drug Industry / economics / Canada Drug Industry / economics / Europe Drug Industry / economics / United States Drug Industry / legislation & jurisprudence / Canada Drug Industry / legislation & jurisprudence / Europe Drug Industry / legislation & jurisprudence / United States Drug Industry economics Canada Drug Industry economics Europe Drug Industry economics United States Drug Industry legislation & jurisprudence Canada Drug Industry legislation & jurisprudence Europe Drug Industry legislation & jurisprudence United States Legislation, Drug economics Canada Legislation, Drug economics Europe Legislation, Drug economics United States Forschung und Entwicklung (DE-588)4017897-3 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Regulierung (DE-588)4201190-5 gnd |
| topic_facet | Legislation, Drug / economics / Canada Legislation, Drug / economics / Europe Legislation, Drug / economics / United States Drug Industry / economics / Canada Drug Industry / economics / Europe Drug Industry / economics / United States Drug Industry / legislation & jurisprudence / Canada Drug Industry / legislation & jurisprudence / Europe Drug Industry / legislation & jurisprudence / United States Drug Industry economics Canada Drug Industry economics Europe Drug Industry economics United States Drug Industry legislation & jurisprudence Canada Drug Industry legislation & jurisprudence Europe Drug Industry legislation & jurisprudence United States Legislation, Drug economics Canada Legislation, Drug economics Europe Legislation, Drug economics United States Forschung und Entwicklung Pharmazeutische Industrie Regulierung Europa Kanada USA |
| work_keys_str_mv | AT buhrlenbernhard theimpactofregulationonthedevelopmentofnewproductsinthepharmaceuticalsectornewproductsandservicesanalysisofregulationsshapingnewmarketsfirstinterimreport AT blindknut theimpactofregulationonthedevelopmentofnewproductsinthepharmaceuticalsectornewproductsandservicesanalysisofregulationsshapingnewmarketsfirstinterimreport AT menradklaus theimpactofregulationonthedevelopmentofnewproductsinthepharmaceuticalsectornewproductsandservicesanalysisofregulationsshapingnewmarketsfirstinterimreport AT fraunhoferinstitutfursystemtechnikundinnovationsforschung theimpactofregulationonthedevelopmentofnewproductsinthepharmaceuticalsectornewproductsandservicesanalysisofregulationsshapingnewmarketsfirstinterimreport |